Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morus alba fruit extract is a botanical derivative from the white mulberry tree, characterized by a rich profile of bioactive compounds including anthocyanins, flavonoids, and the iminosugar 1-deoxynojirimycin (DNJ). It is widely utilized in the nutraceutical industry for its potential to manage postprandial blood glucose levels through the competitive inhibition of alpha-glucosidase and alpha-amylase enzymes in the digestive tract. In the cosmetic sector, the extract is valued for its skin-lightening properties, attributed to its ability to inhibit tyrosinase, the key enzyme in melanogenesis. Beyond these specific actions, its high antioxidant capacity helps mitigate oxidative stress, offering potential protective effects against chronic metabolic and inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morus alba fruit extract.